A clinical study of nafazatrom in advanced human breast cancer.
Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objective remission of metastases was seen in 2 patients and stabilisation of disease in 1 case. Nafazatrom was safe and well tolerated.
Jones
A L
AL
Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, UK.
Powles
T J
TJ
Forgeson
G V
GV
Coombes
R C
RC
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D011453:Prostaglandins / Q000096:biosynthesis; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D047069:Pyrazolones
D000970:Antineoplastic Agents; D011453:Prostaglandins; D011720:Pyrazoles; D047069:Pyrazolones; C018845:nafazatrom